ADMA Biologics shares plunge on short seller allegations By Investing.com

ADMA shares dropped more than 9% after short seller Culper Research disclosed a short and published a report alleging channel stuffing to inflate revenue, estimating 2025 revenues fell 3% versus ADMA's reported 20% growth. Culper cited days sales outstanding rising from 43 to 113 days, $231M adjusted EBITDA versus $50M cash from operations, two distributors (BioCare and CuraScript) representing 73% of revenues and 87% of receivables, third-party ASCENIV sales trailing ADMA’s reported revenues with the gap widening from $14M in 2023 to $121M in 2025, and an implied quarterly revenue range of $59.4M–$74.7M versus roughly $104.4M implied by ADMA’s results.

Analysis

The market is treating the report as an acute credibility shock rather than just a near-term earnings revision; the key second-order mechanism is a forced working-capital unwind at distributors that can amplify revenue declines across 2–4 quarters as excess inventory is run down and payors tighten access. That mechanical destocking creates a cashflow and covenant risk mismatch: earnings that are adjusted upward by non-cash or timing maneuvers will be vulnerable to rapid cash conversion reversals, which is where auditors, lenders and regulators focus their reviews over the next 3–9 months.

A broader payor reaction is the latent channel risk most investors underprice — if major payors treat the product as interchangeable with cheaper alternatives, pricing pressure and utilization edits can persist for years, compressing realized ASPs even if headline patient counts hold. This elevates the probability of multi-year margin compression for niche specialty product sellers while advantaging scale incumbents with broader payer contracts and distribution leverage.

The path to resolution runs through definable catalysts: 1) distributor confirmations/agreements released by the company or distributors (days–weeks), 2) auditor inquiries or non-GAAP reconciliations (weeks–months), and 3) regulatory inquiries or litigation (months–years). Any of the first two could materially revise consensus revenue/cash forecasts; conversely, credible third-party validation of end-user demand would rapidly tighten a short and produce sharp reversals, so position sizing and hedges must be active.

Key Decisions for Investors

• Short ADMA equity (ticker ADMA) sized modestly (2–4% net portfolio exposure). Target 30–50% downside over 3–6 months if a distributor unwind or restatement emerges; hard stop at 15% adverse move. Hedge tail risk with a small long-dated call (3–6 months) or ratio collar to cap max loss.
• Buy 3–6 month ADMA put options (delta ~0.35–0.45) as a concentrated asymmetric play — cost-limited way to capture a potential 2–3x payoff if sales revision + payor tightening materialize. Roll or exit on clear distributor confirmations/audit disclosures.
• Pair trade: short ADMA / long larger, diversified IVIG player (e.g., GRFS or comparable scale incumbent) dollar-neutral sized 1:1 to isolate company-specific channel risk from category demand. Hold 3–9 months; expect convergence if ADMA-specific issues do not reflect broader IVIG fundamentals.
• Tactical reallocation: reduce exposure to ADMA and redeploy into higher-quality growth like SMCI or APP (tickers SMCI, APP) for 3–6 month replacement trades — these offer exposure to durable momentum and should outperform in a risk-off biotech/healthcare re-rating. Keep position sizes disciplined and use stop-losses given macro volatility.